ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1699

Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations

Yidan Wang1, Miranda Gurra1, Carla Cuda1, Hadijat Makinde1, Shangyang Chen1, Gaurav Gadhvi1, Salina Dominguez1, Caroline Shah1, Deborah Winter2 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Skokie, IL

Meeting: ACR Convergence 2022

Keywords: genomics, Monocytes/macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Innate Immunity Poster: Basic and Translational Science

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Monocytes are critical for the pathogenesis of rheumatoid arthritis (RA). However, depletion of circulating monocytes – either classical or non-classical monocytes – is not sufficient to rescue RA in mouse models. Recently, we identified a new cell population of extravascular Ly6c- myeloid cells in the synovial tissue (e.v Syn. Ly6c-) that are distinct from CD64+ macrophages, and required for the development of acute RA-like disease in mouse. Our prior studies suggest that e.v. Syn. Ly6c- in steady state are derived in part from fetal liver that are capable of self-renewal and replenished by circulating monocytes. However, it is unknown whether these ontogenies are associated with different functions over time. A better understanding of the origin of these cells will inform their role in RA and provide avenues for targeted therapies.

Methods: Bone marrow chimeras (BMC) were generated by transferring CD45.1 cells into CD45.2 mice with ankle shielded to preserve the synovial niche. After 8-month post-chimera, mice were injected intravenously (i.v) with anti-CD45 to label i.v immune cells and sacrificed. Blood was analyzed by flow cytometry to confirm chimerism 90% in circulating cells. Clodronate-liposome (clo-lipo) was injected i.v to disrupt the synovial niche. Ankles were dissected during steady state and 1 day after the clo-lipo injection. Flow cytometry was used to quantify CD45.1 and CD45.2 cells. Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) was performed on sorted CD45+CD11b+MHCII-CD64- cells from the synovium during steady state using 10x Genomics and sequenced on Novaseq 6000. CITE-seq data was processed through the CellRanger v6-1.2 and analyzed with the Seurat package v4.1.0. The circulation-derived and tissue-resident e.v Syn. Ly6c- were distinguished based on the antibody derived tag (ADT) expression of CD45.1 and CD45.2.

Results: Our flow results suggested that 67% of e.v Syn. Ly6c- cells were circulation-derived (CD45.1+) during steady-state. After the clo-lipo injection, more than 85% of i.v. Syn. Ly6c- cells got depleted and 64% of e.v Syn. Ly6c- cells were circulation-derived. For CITE-seq, the majority of cells were annotated as either circulating monocytes, e.v Syn. Ly6c- cells, or monocyte-derived dendritic cells based on our prior studies. The e.v Syn. Ly6c- clustered into at least 2 subpopulations with distinct transcriptional profiles, and these subpopulations were distinguished by their CD45 status in ADT level. CD45.2 e.v Syn. Ly6c- exhibited higher levels of genes associated with tissue-residence such as Vsig4 and Lyve1, while CD45.1 cells demonstrated increased expression of immune activation genes, such as S100a10 and Cd52. While these populations had similar surface levels of CD43 and CD14, they differed in CD11C and C5AR.

Conclusion: Our prior studies suggest that the expansion of e.v Syn. Ly6c- cells is a key step in the development of RA. Here, we demonstrate that newly recruited e.v Syn. Ly6c- cells derived from circulation demonstrate a distinct transcriptional phenotype from tissue-resident cells. Future studies will determine how the function of circulation-derived and tissue-resident e.v Syn. Ly6c- cells differ in the development of RA.

Supporting image 1

Figure.1 Flow Cytometry of CD45.1 and CD45.2 e.v Son. Ly6c- cells in A) Steady state and B) after the synovial niche disruption in BMC mice.

Supporting image 2

Figure.2 Uniform Manifold Approximation and Projection (UMAP) of CITE-seq annotated cells of CD45+CD11b+MHCII-CD64- cells from the synovial tissue of BMC mice during steady state.

Supporting image 3

Figure.3 A) RNA and B) ADT markers of CD45.1 and CD45.2 e.v Syn. Ly6c- cells.


Disclosures: Y. Wang, None; M. Gurra, None; C. Cuda, None; H. Makinde, None; S. Chen, None; G. Gadhvi, None; S. Dominguez, None; C. Shah, None; D. Winter, None; H. Perlman, Janssen, kininska, exagen, LEK consultating, Guidepoint.

To cite this abstract in AMA style:

Wang Y, Gurra M, Cuda C, Makinde H, Chen S, Gadhvi G, Dominguez S, Shah C, Winter D, Perlman H. Arthritis-associated Synovial CD64-Ly6c- myeloid Cells Comprise 2 Subpopulations [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/arthritis-associated-synovial-cd64-ly6c-myeloid-cells-comprise-2-subpopulations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arthritis-associated-synovial-cd64-ly6c-myeloid-cells-comprise-2-subpopulations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology